Literature DB >> 9593343

Ultrastructure of atypical (teratoid) sporogonial stages of Enterocytozoon bieneusi (Microsporidia) in naturally infected rhesus monkeys (Macacca mulatta).

D A Schwartz1, D C Anderson, S A Klumpp, H M McClure.   

Abstract

OBJECTIVE: To demonstrate the ultrastructural features of normal and atypical (teratoid) developmental stages of Enterocytozoon bieneusi in naturally infected rhesus monkeys (Macacca mulatta). DESIGN AND METHODS: Two rhesus monkeys with chronic simian immunodeficiency virus infection developed naturally acquired microsporidian infections. The gallbladder had a high parasite burden and was evaluated by transmission electron microscopy. The microsporidian agent was confirmed as E bieneusi by polymerase chain reaction.
RESULTS: In addition to normal sporogonial plasmodia and spores of E bieneusi, abnormal teratoid structures were noted. These structures were greatly enlarged (up to 10 microm) and were surrounded by an electron-dense exospore and electron-lucent endospore typical of mature spores. Unlike mature spores, the abnormal structures contained multiple nuclei and polar tubes in varying proportions, which were reminiscent of sporogonial plasmodia.
CONCLUSIONS: These teratoid structures represent aberrant sporogonial stages, a result of defective maturation in which abnormal cytokinetic replication of organelles occurs, and normal development into uninucleate sporoblasts and spores is inhibited. This leads to the development of teratoid stages having mature spore walls, but containing multiple sets of nuclei and polar tubes, unusual polyribosomal arrays and vacuoles, or persistent cleavage. The biological significance of these atypical spores is unknown, but it is evident that they develop in the absence of antimicrosporidian drugs in extraintestinal tissues from nonhuman primates. Teratoid spores of E bieneusi should not be misinterpreted as another microsporidian species or confused with other pathogenic protozoa, nor should their presence be misconstrued as evidence of antimicrosporidian drug efficacy or toxicity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593343

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  6 in total

1.  Asymptomatic Enterocytozoon bieneusi microsporidiosis in captive mammals.

Authors:  Anna Slodkowicz-Kowalska; Thaddeus K Graczyk; Leena Tamang; Autumn S Girouard; Anna C Majewska
Journal:  Parasitol Res       Date:  2006-10-03       Impact factor: 2.289

2.  Production and characterization of monoclonal antibodies against Enterocytozoon bieneusi purified from rhesus macaques.

Authors:  Quanshun Zhang; Inderpal Singh; Abhineet Sheoran; Xiaochuan Feng; John Nunnari; Angela Carville; Saul Tzipori
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

3.  Monoclonal antibodies against Enterocytozoon bieneusi of human origin.

Authors:  Abhineet S Sheoran; Xiaochuan Feng; Inderpal Singh; Susan Chapman-Bonofiglio; Sabrina Kitaka; Joel Hanawalt; John Nunnari; Keith Mansfield; James K Tumwine; Saul Tzipori
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

4.  Ultrastructure and molecular phylogenetics of Helmichia lacustris, a microsporidium with an uncoiled isofilar polar filament.

Authors:  Yuri S Tokarev; Vladimir N Voronin; Elena V Seliverstova; Tatiana A Grushetskaya; Irma V Issi
Journal:  Parasitol Res       Date:  2011-08-24       Impact factor: 2.289

5.  Ultrastructure and molecular phylogeny of Anisofilariata chironomi g.n. sp.n. (Microsporidia: Terresporidia) from Chironomus plumosus L. (Diptera: Chironomidae).

Authors:  Yuri S Tokarev; Vladimir N Voronin; Elena V Seliverstova; Vyacheslav V Dolgikh; Olga A Pavlova; Anastasia N Ignatieva; Irma V Issi
Journal:  Parasitol Res       Date:  2010-04-07       Impact factor: 2.289

6.  Purification of Enterocytozoon bieneusi from stools and production of specific antibodies.

Authors:  Abhineet S Sheoran; Xiaochuan Feng; Sabrina Kitaka; Linda Green; Christine Pearson; Elizabeth S Didier; Susan Chapman; James K Tumwine; Saul Tzipori
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.